EMA - Joint strategy sets direction for EMA and EU medicines regulatory agencies to 2025

15th December 2020

EMA and the Heads of Medicines Agencies (HMA) have published their joint strategy for the next five years, following its recent adoption by the HMA and EMA Management Board.

Read More+

EMA - Q&A -Types of Studies Needed to Approve a COVID-19 Vaccine

14th December 2020

EMA has published a Question & Answer on what type of studies are needed to approve a COVID-19 vaccine.

Read More+

EMA - News, views and interviews for the Clinical Trials Information System (CTIS)

9th December 2020

CTIS Highlights Newsletter

Read More+

EMA - COVID-19 Vaccines

2nd December 2020

The European Medicines Agency has published information on the development and evaluation of vaccines for COVID-19.

Read More+

EMA - Consideration on core requirements for RMPs of COVID19 vaccines

1st December 2020

Consideration on core requirements for RMPs of COVID19 vaccines coreRMP19 guidance Introduction/Background In addition to the EMA guidance on pharmacovigilance and vaccine development, the EMA will issue the “Pharmacovigilance Plan of the EU Regulatory Network for COVID-19 Vaccines” giving an overview of the monitoring activities to be carried out in the EU for COVID-19 vaccines, including the roles, responsibilities and interactions of the stakeholders involved. Further interactions between EMA, NCAs, and the vaccine manufacturers have identified the need to develop further guidance on RMP requirements for COVID-19 vaccines.

Read More+

EMA - November 2020 PRAC Highlights

1st December 2020

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 November 2020

Read More+

EMA - Pharmacovigilance Plan of the EU Regulatory Network for COVID-19 Vaccines

1st December 2020

Pharmacovigilance Plan of the EU Regulatory Network for COVID-19 Vaccines

Read More+

EMA publishes safety monitoring plan and guidance on risk management planning for COVID-19 vaccines

1st December 2020

EMA and the national competent authorities (NCAs) in EU Member States have prepared a  safety monitoring plan for COVID-19 vaccines . The plan outlines how relevant new information emerging after the authorisation and uptake of COVID-19 vaccines in the pandemic situation will be collected and promptly reviewed.

Read More+

MHRA - Guidance on pharmacovigilance procedures from 1 January 2021

1st December 2020

Content added to Section 2.2, covering the country codes and worldwide case IDs which should be used.

Read More+

MHRA - On-site access to Electronic Health Records by Sponsor representatives in clinical trials

1st December 2020

On-site access to Electronic Health Records by Sponsor representatives in clinical trials The following guidance has been jointly developed by the Heath Research Authority (HRA) and MHRA, in consultation with the Information Commissioners Office (ICO), on behalf of the UK.

Read More+